º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Coronavirus Update: Pharmaceutical boss says sensible planning will get us through crisis

Forward planning will stop shortages, save lives and slow the burden on already stretched NHS

Leicester fans wearing protective masks in the stands at the King Power Stadium

The boss of a º£½ÇÊÓÆµ drug manufacturer has described how preparing for a potential no-deal Brexit had helped his and other suppliers maintain stock availability during the coronavirus outbreak.

Dr Nik Kotecha OBE, who runs prescription drug maker Morningside Pharmaceuticals, said planning for three potential cliff edge Brexits had had a positive knock-on effect ahead of any impact of Covid 19 on supply chains.

Dr Kotecha also said he felt the Government, health authorities and regulators were getting the right balance between taking the necessary steps to slow the spread and avoiding panic.

He added that companies like his had a duty to ensure their continuity planning was up to speed to ensure life-saving medicines got to the people who need them over months ahead.

Loughborough-based Morningside licenses to make 220 different medicines ranging from contraceptives, pain relief and oncology drugs to treatment for conditions such as diabetes.

Dr. Nik Kotecha MBE of Morningside Pharmaceuticals

Dr Kotecha said: “It’s not really having an impact right now, but it could impact on supplies.

“In some ways we are lucky that we had three big deadlines for Brexit and the industry was stocking up. The guidance was to keep six weeks of stock and we were keeping three months worth.

“The biggest concern is that this started in China, where a lot of the raw materials that go into medicines are made.